B Cell Seed Regeneration via RUNX1 HOXA9 LHX2 Co-Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing pluripotent stem cells to differentiate into B cells are inefficient and unstable, failing to produce functional B cells that can sustainably reconstitute the humoral immunity system, particularly lacking in producing essential B2 cells for adaptive immune responses.
Innovation Solution
A method involving the co-expression of RUNX1, HOXA9, and LHX2 genes in pluripotent stem cells, integrated via an expression vector, to direct differentiation into B-lineage seed cells through a series of culture and co-culture steps with stromal cells, resulting in stable and functional B cells post-transplantation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If pluripotent stem cells are induced to differentiate into B cells using conventional methods, then B cell production is achieved, but the efficiency and stability are poor and functional B cells cannot be sustainably reconstituted
Solution Approach 1:
The patent applies preliminary action by pre-differentiating pluripotent stem cells into hemogenic endothelial cells before final B cell differentiation. This two-stage process involves first inducing endothelial cell formation, then converting these to hematopoietic progenitors with B cell potential, thereby improving both efficiency and stability of B cell production
Solution Approach 2:
The differentiation process is segmented into distinct stages: (1) pluripotent stem cell to hemogenic endothelial cell transition, (2) hemogenic endothelial cell to hematopoietic progenitor cell differentiation, and (3) progenitor cell to mature B cell development. This segmentation allows optimization of each stage independently, resolving the contradiction between productivity and reliability
2Duration of action of stationary object
If pluripotent stem cells are differentiated to produce B1 cells, then long-term reconstitution is achieved, but B2 cells essential for adaptive humoral immune response cannot be obtained
Solution Approach 1:
The patent achieves universality by creating a differentiation system that can produce multiple B cell types (B1, B2, and transitional B cells) from a single progenitor population. The hemogenic endothelial cell intermediate stage maintains multipotency, allowing differentiation into various B cell lineages rather than committing to a single B1 or B2 fate, thus providing both long-term durability and functional diversity
3Adaptability or versatility
If specific transcription factors are expressed in pluripotent stem cells to obtain HSPCs, then multi-lineage hematopoietic reconstitution is achieved, but the system has poor stability and relatively low efficiency
Solution Approach 1:
The patent extracts the hemogenic endothelial cell intermediate stage from the direct differentiation pathway. By removing progenitors through this intermediate endothelial stage, the system achieves more stable and efficient B cell production while maintaining the capability for multi-lineage reconstitution, resolving the contradiction between versatility and productivity
Data Source
AI summary
A method for regenerating a humoral immunity system. A pluripotent stem cell is used for expressing a RUNX1 gene, a HOXA9 gene and an LHX2 gene to efficiently obtain B cell seeds after in vitro induction differentiation, and after transplantation, a complete humoral immune system can be reconstructed in an animal in which the humoral immune system is missing. According to the method, an antigen-specific antibody immune response can be realized, a specific high-affinity antibody can be generated against an antigen, and immunological memory can be produced. Meanwhile, the reconstructed immune system is safe, and carries no risk of tumorigenicity.